Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
8.57
+0.06 (0.71%)
At close: Nov 21, 2025, 4:00 PM EST
8.42
-0.15 (-1.75%)
After-hours: Nov 21, 2025, 4:51 PM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$486,290
Market Cap
640.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 3 | 10.71% |
| Dec 31, 2023 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 1 | 3.57% |
| Dec 31, 2021 | 28 | -14 | -33.33% |
| Dec 31, 2020 | 42 | -11 | -20.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVS News
- 18 days ago - Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 22 days ago - Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 25 days ago - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 5 weeks ago - Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Appoints David Moore to Board of Directors - GlobeNewsWire
- 3 months ago - Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
- 3 months ago - Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript - Seeking Alpha